Favipiravir use for SARS CoV-2 infection
INTRODUCTION: The pandemic of SARS CoV-2 has required urgent medical treatments for numerous patients. As no specific antiviral agents were available, different off-the-shelf alternatives have been explored.
OBJECTIVE: Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted.
METHODS: Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent.
RESULTS: This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage.
CONCLUSIONS: Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
Pharmacological reports : PR - 72(2020), 6 vom: 27. Dez., Seite 1542-1552 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boretti, Alberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amides |
|---|
| Anmerkungen: |
Date Completed 07.12.2020 Date Revised 17.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s43440-020-00175-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316772569 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316772569 | ||
| 003 | DE-627 | ||
| 005 | 20231225161813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s43440-020-00175-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316772569 | ||
| 035 | |a (NLM)33108587 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boretti, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Favipiravir use for SARS CoV-2 infection |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2020 | ||
| 500 | |a Date Revised 17.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: The pandemic of SARS CoV-2 has required urgent medical treatments for numerous patients. As no specific antiviral agents were available, different off-the-shelf alternatives have been explored | ||
| 520 | |a OBJECTIVE: Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted | ||
| 520 | |a METHODS: Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent | ||
| 520 | |a RESULTS: This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage | ||
| 520 | |a CONCLUSIONS: Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Animal studies | |
| 650 | 4 | |a Favipiravir | |
| 650 | 4 | |a Human trials | |
| 650 | 4 | |a Laboratory experiments | |
| 650 | 4 | |a SARS CoV-2 | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Pyrazines |2 NLM | |
| 650 | 7 | |a favipiravir |2 NLM | |
| 650 | 7 | |a EW5GL2X7E0 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological reports : PR |d 2005 |g 72(2020), 6 vom: 27. Dez., Seite 1542-1552 |w (DE-627)NLM154978965 |x 2299-5684 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2020 |g number:6 |g day:27 |g month:12 |g pages:1542-1552 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s43440-020-00175-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2020 |e 6 |b 27 |c 12 |h 1542-1552 | ||